Treatment Satisfaction Higher for Patients With RA Choosing Their Own Treatment

TUESDAY, Nov. 3, 2026 (HealthDay News) -- For patients with rheumatoid arthritis (RA), those choosing their own treatment have higher treatment satisfaction, better treatment retention, and fewer reported adverse events, according to a study published online Oct. 27 in RMD Open.Floor L. Reimann, M.D., from Frisius Medical Centre in Leeuwarden, Netherlands, and colleagues conducted a multicenter randomized trial involving patients with biologic disease-modifying antirheumatic drug-naive RA. One hundred two patients were randomly assigned to personally choose between a subcutaneous tumor necrosis factor inhibitor (TNFi) or the oral Janus kinase inhibitor (JAKi) filgotinib or to be randomly assigned to the same treatment options.In the patient-choice group, 55 and 45 percent chose JAKi treatment and subcutaneous TNFi, respectively (28 and 23 patients). The researchers found that treatment satisfaction was significantly higher at 24 weeks in the patient-choice group versus the randomized group. Fewer patients in the patient-choice group switched to a different mode of action by week 12 versus the randomized group. At week 24, the mean Disease Activity Score in 28 joints using erythrocyte sedimentation rate was numerically lower in the patient-choice group, but the difference was not statistically significant. The randomized group used more glucocorticoids at week 12 and had a significantly higher number of adverse events per patient."Our results underscore the importance of patient participation and shared decision-making," the authors write.Several authors disclosed ties to the biopharmaceutical industry.Abstract/Full Text.Sign up for our weekly HealthDay newsletter

Treatment Satisfaction Higher for Patients With RA Choosing Their Own Treatment

Related Stories

Inpatient Rehab, Nursing Facility Or Home? How To Choose The Right Rehab After A Hospital Stay

Patient Reps on FDA Committees Often Have Pharma Ties

Surrogates Less Likely to Recommend Life-Sustaining Treatment for Patients With Dementia

GLP-1s Show Benefit For Kids With Type 2 Diabetes